CAS 35661-60-0|Fmoc-Leu-OH
| Common Name | Fmoc-Leu-OH | ||
|---|---|---|---|
| CAS Number | 35661-60-0 | Molecular Weight | 353.412 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 559.8±33.0 °C at 760 mmHg |
| Molecular Formula | C21H23NO4 | Melting Point | 152-156 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | 292.4±25.4 °C |
Names
| Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
|---|---|
| Synonym | More Synonyms |
Fmoc-Leu-OH BiologicalActivity
| Description | Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Cell Cycle/DNA Damage >>PPARResearch Areas >>Metabolic Disease |
| Target | PPARγ |
| References | [1]. Rocchi S, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001 Oct;8(4):737-47. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 559.8±33.0 °C at 760 mmHg |
| Melting Point | 152-156 °C(lit.) |
| Molecular Formula | C21H23NO4 |
| Molecular Weight | 353.412 |
| Flash Point | 292.4±25.4 °C |
| Exact Mass | 353.162720 |
| PSA | 75.63000 |
| LogP | 4.95 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.583 |
| InChIKey | CBPJQFCAFFNICX-IBGZPJMESA-N |
| SMILES | CC(C)CC(NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O |
| Storage condition | 2~8°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S22-S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2924299090 |
Customs
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles8
More Articles| Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors. Cancer Sci. 106 , 747-56, (2015) L-type amino acid transporter 1 (LAT1), overexpressed on the membrane of various tumor cells, is a potential target for tumor-targeting therapy. This study aimed to develop a LAT1-mediated chemotherap... | |
| Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS ONE 10 , e0126910, (2015) Cardiovascular disease (CVD) is a serious comorbidity in nonalcoholic fatty liver disease (NAFLD). Since plasma ceramides are increased in NAFLD and sphingomyelin, a ceramide metabolite, is an indepen... | |
| Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model. Sci. Rep. 4 , 6777, (2014) Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels ... |
Synonyms
| D-LeuFmoc-OH |
| Fmoc-Leu-OH |
| N-((9H-Fluoren-9-ylmethoxy)carbonyl)-L-leucine |
| EINECS 252-662-7 |
| (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoic acid |
| MFCD00037133 |
| Tocris-0675 |
| FMOC-D-LEU |
| Fmoc-D-Leu-OH |
| Fmoc-L-leucine |
| Fmoc-L-Leu-OH |
| L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- |
| N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-D-leucine |
| Fmoc-D-leucine-OH |
| N-Fmoc-D-leucine |
| D-Fmoc-Leu-OH |
| N-Fmoc-L-leucine |
| D-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- |
| Fmoc-D-Leucine |
| N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine |
